
Diclofenac Potassium, Paracetamol & Chlorzoxazone Tablets
April 17, 2026
Diclofenac Potassium and Serratiopeptidase Tablets
April 17, 2026Diclofenac Sodium and Paracetamol Tablets IP
₹400.00
Product name : TORFLAM-P
Packaging : 10X10 Tablets
Pacitora Biotech presents Torflam-P™, a trusted and widely prescribed fixed-dose combination of Diclofenac Sodium 50mg and Paracetamol 325mg (also known as Acetaminophen). This dual-action formulation is specifically designed for the management of moderate to severe acute pain accompanied by inflammation and/or fever.
Key Benefits:
Dual Action Formula – NSAID + Analgesic/Antipyretic for comprehensive relief.
Powerful Pain Relief – Effective for moderate to severe acute pain.
Reduces Inflammation – Diclofenac targets swelling and inflammation.
Fever Reduction – Paracetamol provides antipyretic action.
Synergistic Effect – Two components work together for enhanced efficacy.
FAQs:
1. What is Torflam-P used for?
Torflam-P is used for moderate to severe acute pain including low back pain, joint pain, dental pain, menstrual cramps, sports injuries, post-surgical pain, and fever with body ache. It is not intended for chronic daily use.
2. How does Torflam-P work?
Diclofenac Sodium reduces inflammation and pain by blocking COX enzymes (peripheral action), while Paracetamol provides additional pain relief and reduces fever through central action. Together they provide stronger relief than either alone.
3. What are the common side effects of Torflam-P?
Common side effects include nausea, stomach discomfort, heartburn, and mild drowsiness. Serious side effects include stomach bleeding (black stools, vomiting blood), severe allergic reactions, or liver problems (yellow skin/eyes).
4. Can I take Torflam-P with other painkillers?
Do not take Torflam-P with any other NSAID (ibuprofen, naproxen, aspirin) or any other paracetamol-containing product. This increases the risk of side effects and overdose. Always inform your doctor of all medications you take.







Reviews
There are no reviews yet.